Subconjunctival aflibercept for the treatment of formed corneal neovascularization

Ruti Sella*, Meydan Ben Ishai, Eitan Livny, Yoav Nahum, Irit Bahar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Purpose: To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. Methods: A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti-vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Bestcorrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. Results: Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection (P.0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. Conclusions: A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.

Original languageEnglish
Pages (from-to)180-184
Number of pages5
JournalEye and Contact Lens
Issue number4
StatePublished - 1 Apr 2021


FundersFunder number
Claire and Amedee Maratier Institute for the Study of Blindness
Visual Disorders
Sackler Faculty of Medicine, Tel-Aviv University


    • Aflibercept
    • Clinical trial
    • Corneal neovascularization
    • Eylea


    Dive into the research topics of 'Subconjunctival aflibercept for the treatment of formed corneal neovascularization'. Together they form a unique fingerprint.

    Cite this